172 related articles for article (PubMed ID: 22677995)
1. Management of advanced genitourinary tumors.
Pietrantonio F; Biondani P; Verzoni E; Procopio G
Tumori; 2012; 98(2):264-6. PubMed ID: 22677995
[TBL] [Abstract][Full Text] [Related]
2. New perspectives in advanced genitourinary malignancies.
Biondani P; Procopio G; Pietrantonio F; de Braud F; Verzoni E
Tumori; 2012; 98(2):267-9. PubMed ID: 22677996
[TBL] [Abstract][Full Text] [Related]
3. Imaging in genitourinary cancer from the urologists' perspective.
Tsakiris P; de la Rosette J
Cancer Imaging; 2007 May; 7(1):84-92. PubMed ID: 17535776
[TBL] [Abstract][Full Text] [Related]
4. Genitourinary cancer.
Hudes GR; Ozols RF; Schilder RJ
Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
[No Abstract] [Full Text] [Related]
5. Role of multidrug resistance in tumors of the genitourinary tract.
Theyer G; Hamilton G
Urology; 1994 Dec; 44(6):942-50. PubMed ID: 7985331
[No Abstract] [Full Text] [Related]
6. Genitourinary malignancies.
Michaelson MD; Smith MR
Cancer Chemother Biol Response Modif; 2003; 21():547-64. PubMed ID: 15338763
[No Abstract] [Full Text] [Related]
7. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract][Full Text] [Related]
8. Optimizing utilization of targeted therapies in genitourinary cancers.
Bukowski RM
Clin Genitourin Cancer; 2008 Dec; 6 Suppl 1():S6. PubMed ID: 19891123
[No Abstract] [Full Text] [Related]
9. Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
Valls L; Hoimes C; Sher A; Hu L; Lee Z; Muzic R; Avril N
Semin Roentgenol; 2014 Jul; 49(3):238-41. PubMed ID: 25497908
[No Abstract] [Full Text] [Related]
10. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
11. [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].
Stattaus J; Bockisch A; Forsting M; Müller SP
Urologe A; 2005 Jun; 44(6):614-24. PubMed ID: 15905989
[TBL] [Abstract][Full Text] [Related]
12. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
[TBL] [Abstract][Full Text] [Related]
13. Future directions for gemcitabine in the treatment of genitourinary cancer.
Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1 Suppl 3):40-5. PubMed ID: 11894007
[TBL] [Abstract][Full Text] [Related]
14. Practical Molecular Testing in a Clinical Genitourinary Service.
Magers MJ; Cheng L
Arch Pathol Lab Med; 2020 Mar; 144(3):277-289. PubMed ID: 31373513
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib in genitourinary malignancies.
Zhang T; Park SE; Hong C; George DJ
Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
[TBL] [Abstract][Full Text] [Related]
16. [Why is PET/CT essential in urooncology?].
Borbély K; Géczi L; Kásler M
Magy Onkol; 2013 Dec; 57(4):282-96. PubMed ID: 24353995
[TBL] [Abstract][Full Text] [Related]
17. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
18. Biennial report on genitourinary cancers.
Fizazi K
Eur J Cancer; 2016 Oct; 66():125-30. PubMed ID: 27569040
[TBL] [Abstract][Full Text] [Related]
19. A review of therapeutic strategies for phase I-II trials in genitourinary cancer.
Friedman MA
Recent Results Cancer Res; 1980; 70():203-10. PubMed ID: 7188814
[No Abstract] [Full Text] [Related]
20. Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Tanaka Y; Hagiwara K; Hirai H; Morohashi S; Kijima H; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Oncotarget; 2017 Jul; 8(30):49749-49756. PubMed ID: 28572534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
